Valneva SE (VALN)

Market Cap	576.09M
Revenue (ttm)	176.82M
Net Income (ttm)	-8.27M
Shares Out	140.53M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,270
Open	6.91
Previous Close	7.03
Day's Range	6.80 - 6.91
52-Week Range	3.62 - 9.50
Beta	1.11
Analysts	Strong Buy
Price Target	17.00 (+148.66%)
Earnings Date	May 6, 2025

About VALN

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 6, 2021
• Employees: 676
• Stock Exchange: NASDAQ
• Ticker Symbol: VALN
• Website: https://valneva.com

Financial Performance

In 2023, Valneva SE's revenue was 153.71 million, a decrease of -57.46% compared to the previous year's 361.30 million. Losses were -101.43 million, -29.21% less than in 2022.

Financial numbers in EUR

Analyst Forecast

According to 2 analysts, the average rating for VALN stock is "Strong Buy." The 12-month stock price forecast is $17.0, which is an increase of 148.66% from the latest price.

Price Target

$17.0

(148.66% upside)

Analyst Consensus: Strong Buy